AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02477618
Drug: SAGE-547
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02198027
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
Trial: NCT03961165
Drug: Butylscopolamine Bromide 20 MG/ML
RxNorm normalized name: butylscopolamine bromide 20 MG/ML
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
Trial: NCT03961165
Drug: Sodium Chloride 9mg/mL
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
Trial: NCT00428350
Drug: Quetiapine Fumarate (Seroquel)
RxNorm normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003718
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03053050
Drug: SEL
RxNorm normalized name: Selen
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT00104572
Drug: Androgel (Testosterone Gel)
RxNorm normalized name: testosterone Topical Gel [Androgel]
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg tablet for 12 months
Trial: NCT00104572
Drug: Anastrozole (Aromatase Inhibitor)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03010683
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
Trial: NCT03010683
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
Trial: NCT04469777
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Trial: NCT00537511
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00537511
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00537511
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02333591
Drug: GlucagonLikePeptide-1 (7-36)
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
Trial: NCT02333591
Drug: GlucagonLikePeptide-1 (9-36)
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
Trial: NCT02333591
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused intravenously for 2,5 hours.
Trial: NCT01204697
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 intravenously every 3 weeks for 4 cycles
Trial: NCT01204697
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
Trial: NCT01204697
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/day orally as monotherapy
Trial: NCT01682577
Drug: Perindopril 4 mg tablets of PT Dexa Medica
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Trial: NCT01682577
Drug: Perindopril 4 mg tablets of Servier
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Trial: NCT02373241
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dosing
Trial: NCT02373241
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dosing
Trial: NCT01707329
Drug: Icotinib+chemotherapy
RxNorm normalized name: Nicotine
DrugBank: Icotinib (DB11737)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Trial: NCT01174953
Drug: finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)
Trial: NCT03104855
Drug: d6-25-hydroxyvitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of stable isotope-labeled D6-25(OH)D3
Trial: NCT00457483
Drug: hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg once-a-day
Trial: NCT00457483
Drug: valsartan, 80 mg once-a-day
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg once-a-day
Trial: NCT00664755
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study.
Trial: NCT00104078
Drug: MYO-029
RxNorm normalized name: MYO-029
DrugBank: Stamulumab (DB05915)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04094766
Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
Trial: NCT03982186
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
Trial: NCT03714919
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral dextromethorphan 1 mg/kg
Trial: NCT03714919
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative intravenous dexmedetomidine 0.5 μg/kg
Trial: NCT03982186
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 tablets will be administered orally.
Trial: NCT03714919
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous ketamine 0.5 mg/kg
Trial: NCT02287402
Drug: AO-128
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-128 tablet
Trial: NCT04247815
Drug: ATI-450
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, small molecule MK2 inhibitor
Trial: NCT02593110
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
Trial: NCT01447043
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Trial: NCT00253721
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days
Trial: NCT00791895
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treat-to-target dose titration scheme
Trial: NCT02171780
Drug: BI 1744 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04646876
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prospective , comparative , double blind study
Trial: NCT01168752
Drug: Debio 0932
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met.
Trial: NCT00256399
Drug: Alfuzosin 10 mg
RxNorm normalized name: alfuzosin 10 mg oral tablet, extended release
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00251745
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Trial: NCT00251745
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
Trial: NCT04202380
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
Trial: NCT01301729
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
Trial: NCT01301729
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
Trial: NCT01301729
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
Trial: NCT03071276
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally on days 1,3,8,10,22 and 24 of each cycle
Trial: NCT03071276
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Trial: NCT03071276
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
Trial: NCT02796053
Drug: TAB08
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The TAB08 will be administered intravenously, by infusion.
Trial: NCT00426439
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Trial: NCT03123068
Drug: CocoaVia®
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
Trial: NCT00265369
Drug: Spores of Bacillus Clausii Probiotic Strain
RxNorm normalized name: Bacillus clausii
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01748929
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04429516
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
Trial: NCT04137042
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative fluid therapy is administrated by using 0.9% saline
Trial: NCT01911273
Drug: PF-03446962
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
Trial: NCT00262665
Drug: ORG 24448
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Trial: NCT00004263
Drug: 7-hydroxystaurosporine (UCN-01)
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
Trial: NCT00004263
Drug: Cytarabine (Ara-C)
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
Trial: NCT02216097
Drug: PF-04457845
RxNorm normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg PF-04457845 tablet taken once daily for 7 days.
Trial: NCT02500602
Drug: doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active medication
Trial: NCT02445599
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg Dormicum intramuscularly, administered 1 hour before surgery
Trial: NCT02445599
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg Atropine intramuscularly, administered 1 hour before surgery
Trial: NCT02790853
Drug: Proflavine Hemisulfate
RxNorm normalized name: Proflavine hemisulfate
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied on mucosa
Trial: NCT03009045
Drug: Tedizolid
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg oral tedizolid one pill per day
Trial: NCT02445599
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1st choice for rescue analgetic 10-20 mg intravenously
Trial: NCT02445599
Drug: Metamizole-sodium
RxNorm normalized name: metamizole sodium
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional rescue analgetic 2g intravenously
Trial: NCT02445599
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Additional rescue analgetic 100mg intravenously
Trial: NCT04011124
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose on Day 1 and Day 12
Trial: NCT04011124
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QD on Day 5-14 for 10 days
Trial: NCT03161340
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will take Rapamycin 2 days before IVF until 15 days after IVF
Trial: NCT02350816
Drug: HGT-1410
RxNorm normalized name: HGTV-43
DrugBank: HGTV-43 (DB05807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGT-1410 administered according to Patient Group assignment.
Trial: NCT04493567
Drug: BMS-986036
RxNorm normalized name: BMS-986036
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01453179
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
Trial: NCT03172494
Drug: Insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Trial: NCT03172494
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Trial: NCT03172494
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks.
Trial: NCT03939663
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol 2 tablets
Trial: NCT02764151
Drug: PF-06840003
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Oral PF-06840003
Trial: NCT00797589
Drug: HES
RxNorm normalized name: HES
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml/kg as prime fluid
Trial: NCT00281957
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00281957
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00281957
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02523300
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The other 120 patients will be given saline as control group
Trial: NCT00773474
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
Trial: NCT00226980
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00732485
Drug: fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
Trial: NCT00451178
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
Trial: NCT00451178
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
Trial: NCT00451178
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Trial: NCT00451178
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, oral, Days 1-5, six 21-day cycles